Key Benefits of the Report to your business
- Identify and evaluate the scale of growth opportunities across 14
key markets for generics producers - including small, growing and little
understood markets
- Benchmark competitors and peers in each market using recently
researched company profiles, featuring latest intelligence on more than 50
generics companies, analysing competitive positioning, opportunities, risks
and strategies of each company
-
Benchmark your own views and forecasts for market performance
against BMI's independent 5-year industry forecasts for generics and
patented drugs
-
Use BMI's country-comparative business environment ratings to assess
the operating risks, opportunities and key factors impacting corporate
profitability in each of the 14 markets covered
Extracts from Generics Producers in Asia: Where Are the Big Opportunities?
Of the 14 markets covered in the Report, all but two (Taiwan and Thailand) will experience double-digit growth over the next five years. Malaysia will expand fastest, as it looks to reduce reliance on imported patented medications and stimulate local industry.
In China, which buys more generic drugs than any other country in Asia (US$20bn of these medicines were consumed last year), but cannot meet demand by internal production, we anticipate market consolidation.
The leading producer of generic drugs in Asia is India. Through to 2012, generics will continue to account for the vast majority of drug consumption in the country (and just over 40% of total spending), largely owing to their low cost and the limited purchasing power of most of the population. Annual per capita spending is US$4.30, above Indonesia (US$4.04), the Philippines (US$3.35) and neighbouring Pakistan (US$1.22). We show how, in recent years, India has started to export large amounts of generics to the international market, which has proved highly lucrative.
Find out why BMI expects 2008 to be a watershed year for the Philippines generic drug sector, as legislation is brought in to reduce drug prices and increase access to medicines. We also anticipate increased generic drug sales in Australia, on the back of further export 'springboarding'; despite having one of the smallest populations in the region, Australia has the fifth largest generic drug sector (US$1.38bn). South Korea boasts the highest annual per capita spending in the region, at US$111 - surprising considering that the vast majority of the public are unaware of generic substitution.
Generics Producers in Asia: Where Are the Big Opportunities highlights another key feature of the Asian generic drugs sector: small, but growing, markets. Combined sales in Singapore and Hong Kong were just US$230mn last year, or 0.5% of the regional market. While this is a disincentive to drugmakers, both these countries have relatively stable economic and political environments, which goes a long way to protecting investments. We show how emerging Asian markets such as Laos, Brunei Darussalam, Sri Lanka, Nepal and Cambodia will all become more attractive markets over our forecast period.
|
